Ibex Wealth Advisors Purchases New Position in SPDR S&P Biotech ETF $XBI

Ibex Wealth Advisors bought a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 1st quarter, HoldingsChannel reports. The firm bought 6,918 shares of the exchange traded fund’s stock, valued at approximately $884,000.

Several other hedge funds also recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of SPDR S&P Biotech ETF during the fourth quarter valued at about $27,000. Financial Life Planners purchased a new position in shares of SPDR S&P Biotech ETF during the 1st quarter valued at $27,000. Intesa Sanpaolo Wealth Management bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter worth $30,000. SHP Wealth Management purchased a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter worth $31,000. Finally, Legacy Wealth Managment LLC ID purchased a new position in SPDR S&P Biotech ETF during the fourth quarter worth about $32,000.

SPDR S&P Biotech ETF Stock Up 0.8%

Shares of NYSEARCA XBI opened at $164.28 on Friday. The firm has a market capitalization of $11.19 billion, a P/E ratio of 11.47 and a beta of 0.82. The stock’s 50-day simple moving average is $139.81 and its two-hundred day simple moving average is $131.18. SPDR S&P Biotech ETF has a twelve month low of $84.39 and a twelve month high of $165.71.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.